New hope for stubborn psoriasis: drug tested when other treatments fail
NCT ID NCT06336343
Summary
This study is testing whether the drug bimekizumab can help people with moderate-to-severe plaque psoriasis when other similar medications have not worked. It will involve 60 adults who previously tried and did not respond well to treatments targeting IL-17 or IL-23. Participants will receive bimekizumab injections over 16 weeks to see if it reduces their psoriasis coverage and severity.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact Phone: •••-•••-••••
Contact
-
Windsor Dermatology - Psoriasis Treatment Center of Central New Jersey
RECRUITINGEast Windsor, New Jersey, 08520, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.